Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Corporate Update (January 2019)

39 slides from Windtree Therapeutics's corporate update, Jan 3, 2019

  1. Slide 1: Investor Conference Call

    Ee we WINDTREE THERAPEUTICS™ Investor Conference Call January 3, 2019 OTCQB:WINT

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: Windtree Focused on Addressing the Company Needs While Creating an Opportunity

    Windtree Focused on Addressing the Company Needs While Creating an Opportunity to Strengthen Our Company = Mid-2017: After completing the AEROSURF® = In 2H 2017, we executed a financial Phase 2b, we needed to: restructuring initiative that resulted in: * Develop anew, phase 3 Aerosol * Retirement of

  4. Slide 4: CVie Therapeutics

    CVie Therapeutics GO CVie Therapeutics = Headquartered in Taipei, Taiwan with additional preclinical operations in Milan, Italy = Privately held - investors included Kleiner Perkins Caufield Byers (KPCB), Bioengine, Lee’s Pharm, Lilly Asia Ventures, Yuanta Securities and China Development Industrial

  5. Slide 5: Merger with CVie Therapeutics

    Merger with CVie Therapeutics The merger followed nearly a year of extensive and comprehensive diligence, governance, negotiation and other good practices. Windtree’s direct wholly-owned subsidiary merged with and into CVie, with CVie surviving as a wholly-owned sub of Windtree in an all-stock trans

  6. Slide 6: Merger with CVie Therapeutics (cont'd)

    Merger with CVie Therapeutics (cont’d) = In connection with the Merger, Lee’s Pharmaceutical Holdings Limited (Lee’s), which owned 49.58% of the outstanding shares of CVie prior to the Merger, agreed to indemnify the Windtree shareholders of record on December 20, 2018 for losses resulting from any

  7. Slide 7: $39.0 Million Private Placement

    $39.0 Million Private Placement = Concurrent with the closing of the merger, Windtree completed a private placement of 11.8 million common stock shares at a per share purchase price equal to $3.3132 (10% discount from the 15-day average closing price as of December 17, 2018) for gross proceeds of $3

  8. Slide 8: Rationale for Merger and Financing

    Rationale for Merger and Financing - Creating a Stronger Company with More Opportunity = CVie and Windtree each have attractive product assets addressing significant unmet medical needs and valuable market opportunities. = Windtree’s management team has extensive experience in: developing and commer

  9. Slide 9: Windtree Post-Merger Global Company

    Windtree Post-Merger Global Company = Public, biopharmaceutical / medical device company with a current + market cap of approximately $160MM = Headquarters in Pennsylvania, USA with operations in Taipei, Taiwan and research in Milan, Italy = Late-stage development company primarily focused on acute

  10. Slide 10: Diversified, Late-Stage Development with Robust Pipeline

    Diversified, Late-Stage Development with Robust Pipeline qlstaroxime AEROSURF® for the Treatment of Acute Heart Failure fees for non-invasive treatment of RDS Gems Se @w@ WINDTREE THERAPEUTICS” Rostafuroxin Lucinactant for genetically associated hypertension and LS renal impairment for RDS treatment

  11. Slide 11: Istaroxime for the Treatment of Acute Heart Failure

    "gy istaroxime § for the Treatment of Acute Heart Failure SQ winotREe

  12. Slide 12: Heart Failure is a Significant Healthcare Issue

    Heart Failure is a Significant Healthcare Issue = There are more than 6 million patients with heart failure in the U.S. and over 18 million worldwide = Heart Failure is the #1 reason for hospitalizations in patients >60 years old ¢ >1 million hospitalizations per year © 50% of patients will readmit

  13. Slide 13: Heart Failure

    Heart Failure = Impaired myocardial contractility is characteristic of heart failure; pulmonary congestion and edema are typical features = Inadequate forward flow of blood contributes to other organs failing in these patients = Mainstays of chronic therapy include diuretics, inhibitors of neurohumo

  14. Slide 14: Significant Unmet Medical Need Exists

    Significant Unmet Medical Need Exists = Patients presenting with acute decompensated heart failure are often complex and difficult to manage = Current approaches to acutely improve cardiac function (inotropes) are associated with potential unwanted effects ¢ Heart rhythm disturbances ¢ Increased hea

  15. Slide 15: Istaroxime

    Istaroxime = Novel intravenous agent designed to improve systolic and diastolic function of the heart = Dual mechanism of effect—luso-inotropic ¢ Inhibition of the sodium-potassium pump and effects on the sodium- calcium exchanger results in more calcium available for contraction Inotropic effect (s

  16. Slide 16: Istaroxime Phase 2a Study

    Istaroxime Phase 2a Study = This study of 120 patients evaluated 3 doses of istaroxime over a 6 hour infusion in hospitalized patients with heart failure and LVEF (Left Ventricular Ejection Fraction) < 35% = Results: ¢ The primary endpoint, lowering of PCWP (pulmonary capillary wedge pressure), was

  17. Slide 17: Istaroxime Phase 2b Study Topline Results

    1p SS Z Istaroxime Phase 2b Study Topline Results = A phase 2b study of 2 doses of istaroxime compared to placebo has recently been completed in 120 patients hospitalized for acute decompensated heart failure. Key trial characteristics included: © LVEF < 40%, elevated BNP (a marker of worsening hear

  18. Slide 18: Istaroxime Phase 2b Study Topline Results

    Istaroxime Phase 2b Study Topline Results = Importantly, there was a relative absence of common complications associated with currently available inotropes. ¢ Istaroxime infusion did not appear to: — Increase arrhythmias — Increase troponin (no heart muscle damage) ¢ Additionally — Heart rate was de

  19. Slide 19: Istaroxime Next Steps

    Istaroxime Next Steps * Having just completed a Phase 2b study and with the post-merger data integration, we will be conducting a detailed analysis of the complete Phase 2b results beyond the topline data * Our goal is to transition Ista to Phase 3. We will be utilizing heart failure experts and eng

  20. Slide 20: More Opportunity Provided By Two Additional Preclinical Heart Failure Programs

    More Opportunity Provided By - Two Additional Preclinical Heart Failure Programs Selective SERCA2a Oral AHF Candidates Candidate = SERCA2a with pure = Oral, dual-mechanism stimulatory activity, but Na*/K* pump and SERCA2a devoid of any Na*/K* drug candidate ATPase inhibitory = Would serve as a follo

  21. Slide 21: Rostafuroxin

    Rostafuroxin for genetically associated hypertension and renal impairment SQ winotREe

  22. Slide 22: Hypertension Market

    Hypertension Market * Hypertension is a very large market with high unmet need * Over 1/3 of the adult population in the U.S. has hypertension and the incidence is increasing * Hypertension is a very heterogeneous disease and it is well known that ethnicity can impact response to different classes o

  23. Slide 23: Rostafuroxin

    Rostafuroxin = Uncontrolled hypertension has been associated with certain genetic makeup ¢ Adducin polymorphisms and endogenous ouabain can trigger hypertension by enhancing renal tubular sodium reabsorption and increasing vascular tone = Rostafuroxin is designed to be a potent and selective antagon

  24. Slide 24: Rostafuroxin Reduced Blood Pressure in Caucasians with Select Mutation

    Rostafuroxin Reduced Blood Pressure in Caucasians with Select Mutation in Both Phase 2a and Phase 2b Trials * Clinical Objective of the Phase 2b Study: Examine antihypertensive effect of different doses of ROSTAFUROXIN (6, 50 and 500 ug) in comparison with Losartan (50 mg), assessed by office and am

  25. Slide 25: Differential Response to Rostafuroxin in the PEARL 2b Study

    Differential Response to Rostafuroxin in the PEARL 2b Study While the BP reduction in Caucasians was notable in two trials, blood pressure response in Chinese patients was significantly less pronounced: SBP fall % responders o 50 500 80 5 5 60 wg710 40 = E-15 mCAU 20 | 58 =cH “ 0! 50 ng 500 ne -25 J

  26. Slide 26: Rostafuroxin Moving Forward

    Rostafuroxin Moving Forward Strategy: Large pharmaceutical companies have interest in this area as evidenced by recent hypertensive agents in licensing deals. These companies are well equipped to develop and commercialize these agents. Our strategy is to do the work necessary to position Rostafuroxi

  27. Slide 27: AEROSURF

    eer

  28. Slide 28: AEROSURF Update

    AEROSURF® Update = The Company previously reported on multiple sets of safety and efficacy related data from our Phase 2 studies including the observations and clinical learnings: v meaningful nCPAP failure reduction at 80mg/kg across phase 2 clinical trials when dosed as intended Y significantly im

  29. Slide 29: AEROSURF Phase Program Latest Data - Decreased BPD Incidence and Severity

    AEROSURF® Phase 2 Program Latest Data - Decreased BPD Incidence and Severity Bronchopulmonary Dysplasia (BPD), a chronic lung disease of the newborn who have required intubation, mechanical ventilation and oxygen therapy. BPD is associated with ongoing pulmonary disease, neurodevelopmental impairmen

  30. Slide 30: AEROSURF Has the Potential to Impact the Clinical Course of RDS

    AEROSURF® has the Potential to Impact the Clinical Course of RDS 1 year Hospitalization Data (elie SBE . ‘) treatment Available in Q2 2019 ri Ale a Reduced Rates Improved and Severity of Respiratory i BPD Parameters sieRatio —/ / ‘ety ta wy AEROSURF® 7 | ae | | Post-hocpooled analysis of Phase? fail

  31. Slide 31: AEROSURF Clinical Development Next Steps

    AEROSURF® Clinical Development Next Steps Generate the strongest possible position for transition to Phase 3 Execute a Bridge Study to transition the new, Phase 3 /commercial platform ADS device in order to meet the following objectives: 1. Demonstrate adequate, consistent performance with the new A

  32. Slide 32: AEROSURF Bridge Study Design

    AEROSURF® Bridge Study Design Blinded study; nCPAP alone as control versus adding AEROSURF® treatment GA range: 26-32 weeks N=70 planned (35 per group) ina design similar to Phase 2b ~20-25 select sites * represent the best previous study sites for enrollment and execution in Phase 2 (predominate U.

  33. Slide 33: Mitigating Risks and Strengthening Our Approach

    Mitigating Risks and Strengthening Our Approach AEROSURF® Program Evolution and Changes = We have reproduced reductions in nCPAP failure in our phase 2a and 2b studies = Utilize the new, phase 3 / intended commercial platform ADS, which is designed to mitigate the risk of treatment interruptions exp

  34. Slide 34: Windtree Late and Early Stage Programs

    “—~ Windtree Late and Early Stage Programs ) Expanded Pipeline of Cardio / Pulmonary Phase 3 Istaroxime acute heart failure Rostafuroxin genetically associated HTN AEROSURF RDS (non-invasive) Lucinactant LS RDS Eleison Oncology ADS for inhaled cisplatin Cv-IST2 oral forheartfailure SERCA2a acute hea

  35. Slide 35: Value Creating Milestone Opportunities

    Value Creating Milestone Opportunities: Robust Short and Mid Term Binary Events New Flow \ Merger Transaction + Financing Istaroxime Phase 2b data Potential NASDAQ Up listing Istaroxime Phase 3 start Short-_| Term Rostafuroxin other data and possible deal AEROSURF® Bridge Study results (transition t

  36. Slide 36: 2019 Preliminary Objectives

    2019 Preliminary Objectives 1. “Right fromthe Start” - Post-merger integration and drive focus, alignment and execution with rigor 2. _ Istaroxime: transition to Phase 3 readiness 3. AEROSURF®: Solid execution of Bridge Study start-up 4. Potential relisting on NASDAQ to support increased price and v

  37. Slide 37: Financial Position Update

    Financial Position Update ™ Cash and cash equivalents (net of $3.0 million in estimated transaction related fees) of $29 million as of December 21, 2018 = Assumed $8.0 million of debt from CVie * $4.5 million in a bank credit facility currently due in March 2020 * $3.5 million due to Lee’s Pharmaceu

  38. Slide 38: Current Capital Summary

    Current Capital Summary (in millions of shares) Common Stock 32.1 Warrants AEROSURF Warrants (merger warrants expiring December 2023) 3.0 December 2018 Private Placement ($3.68 exercise price ; expiring June 2020) 2.0 December 2018 Private Placement ($4.05 exercise price ; expiring December 2023) 3.

  39. Slide 39: Potential Benefits of Transaction to Windtree Current and Future Shareholders

    Potential Benefits of Transaction to Windtree Current and Future Shareholders - Enhanced Trajectory and Opportunity for Value Generation 1. Attractive product assets and diversification could yield multiple short to mid term value-inflection and growth opportunities as well as helping to spread of r

Windtree Therapeutics — Corporate Update (January 2019) on 6ix